Vandetanib
- Generic Name
- Vandetanib
- Brand Names
- Caprelsa
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24BrFN4O2
- CAS Number
- 443913-73-3
- Unique Ingredient Identifier
- YO460OQ37K
- Background
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
- Indication
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
- Associated Conditions
- Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer
- Associated Therapies
- -
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT06482086
- Locations
- 🇨🇳
West China hospital, Chengdu, Sichuan, China
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT04760288
- Locations
- 🇪🇸
Hospital Universitario Virgen del Rocio, Sevilla, Spain
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 291
- Registration Number
- NCT04211337
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2021-07-14
- Target Recruit Count
- 6
- Registration Number
- NCT03630120
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT02638428
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Velindre NHS Trust
- Target Recruit Count
- 160
- Registration Number
- NCT02530411
- Locations
- 🇬🇧
Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom
🇬🇧Velindre Cancer Center, Velindre Hospital, Cardiff, Wales, United Kingdom
🇬🇧Royal United Hospital Bath, Bath, United Kingdom
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 7
- Registration Number
- NCT02495103
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- Drug: AZD2014Drug: AnthracyclinesDrug: MEDI4736Drug: AZD4547Drug: TaxanesDrug: AZD5363Drug: cyclophosphamideDrug: DNA intercalatorsDrug: AZD8931Drug: SelumetinibDrug: MethotrexateDrug: vinca alkaloidsDrug: VandetanibDrug: Platinum based chemotherapiesDrug: BicalutamideDrug: OlaparibDrug: BevacizumabDrug: Mitomycin CDrug: Eribulin
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1460
- Registration Number
- NCT02299999
- Locations
- 🇫🇷
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France
🇫🇷Institut Claudius Regaud, Toulouse, France
🇫🇷Hopitaux Du Leman, Thonon-les-Bains, France
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
- Conditions
- Interventions
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 15
- Registration Number
- NCT02239952
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Noord-Holland, Netherlands
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 999
- Registration Number
- NCT02117167
- Locations
- 🇫🇷
HĂ´pital Avicenne, Bobigny, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Institut Paoli Calmettes, Marseille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.